Copyright
©2014 Baishideng Publishing Group Inc.
World J Transl Med. Dec 12, 2014; 3(3): 119-132
Published online Dec 12, 2014. doi: 10.5528/wjtm.v3.i3.119
Published online Dec 12, 2014. doi: 10.5528/wjtm.v3.i3.119
Peptide | Production site | Effect | After bariatric surgery | Potential pharmaceutical intervention |
Ghrelin | Stomach, mainly fundus | Appetite stimulating | ↓ | Receptor antagonists |
Growth hormone releasing | GOAT inhibition | |||
Vaccination | ||||
GLP-1 | L-cells of the distal small bowel | Postprandialinsuline secretion | ↑ | Weight loss in patients with diabetes |
Suppresses glucagon secretion | Off-label use in obese patients | |||
Delays gastric emptying | ||||
Suppresses appetite | ||||
GIP | Duodenum, jejunum | Postprandial insulin secretion | ↓ | GIP receptor antagonist |
Energy expenditure | ||||
CCK | Duodenum, jejunum | Delays gastric emptying | ↑ | CCK analogue substance |
Suppresses appetite | ||||
PYY | Distal small bowel | Delays gastric emptying | ↑ | Long-acting analogue substance |
Suppresses appetite | ||||
PP | Distal small bowel | Suppresses appetite | ↔ | PP analogue substance |
OXM | L-cells of the distal small bowel | Delays gastric emptying | ↑ | Receptor agonist |
Suppresses appetite | ||||
Increase energy expenditure |
- Citation: El Gammal AT, Dupree A, Wolter S, Aberle J, Izbicki JR, Güngör C, Mann O. Obesity research: Status quo and future outlooks. World J Transl Med 2014; 3(3): 119-132
- URL: https://www.wjgnet.com/2220-6132/full/v3/i3/119.htm
- DOI: https://dx.doi.org/10.5528/wjtm.v3.i3.119